Action

Virtual QI Workshop Opportunity - Improving HR+/HER2- Metastatic Breast Cancer Patient Care

ACCC is inviting up to 3 cancer programs to participate in a virtual, expert-led quality improvement workshop in Summer 2025 focused on enhancing quality of life for patients with advanced hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer. Participating programs will receive:

• Exclusive Expert Guidance. Your multidisciplinary team will engage in a virtual, interactive workshop led by experts in the field.
• Financial Support. Your program will receive a $15,000 stipend for participation and follow-up engagement.
• Recognition and Impact. Key stakeholders may have the opportunity to contribute to an abstract submission showcasing your program’s success.
• Continued Support. Participate in brief 3-month and 6-month virtual follow-ups to track progress and share insights.

Interested programs should email tvanoort@accc-cancer.org by Monday, July 7.

ACCC Welcomes its Newest Members

• John Muir Health
  Walnut Creek, California
  Delegate Rep: Carolina Godinez
  Website: johnmuirhealth.com
• American Oncology Network
  Fort Myers, Florida
  Delegate Rep: Anne Marie Rainey
  Website: aoncology.com
• American Oncology Network – Western Region Programs
  Fort Myers, Florida
  Delegate Rep: Amber Pierce
  Website: floridaonc.com
• American Oncology Network – Central Region Programs
  Fort Myers, Florida
  Delegate Rep: Stacey Hield
  Website: floridaonc.com
• American Oncology Network – Eastern Region Programs
  Fort Myers, Florida
  Delegate Rep: Heather Wenberg
  Website: floridaonc.com

ACCC Position Statement: Protecting Cancer Research and Patient Care Access

ACCC strongly opposes recent executive actions limiting NIH funding and other federal support for medical research and the House budget resolution that would reduce Medicaid funding. These changes threaten to undermine cancer research infrastructure, reduce patient access to care, and reverse progress in cancer treatment outcomes nationwide. Read the full statement on the ACCC website.

ACCC Offers a New Continuing Education Opportunity

This continuing education opportunity provides guidance on managing HR+, HER2- metastatic breast cancer and is designed for physicians, nurses, pharmacists, physician assistants, and the entire multidisciplinary cancer care team. The course explores first-, second-, and third-line therapies for disease progression, strategies to manage treatment-related toxicities, and approaches to enhance patients’ quality of life.

ACCC Releases 2 New Resource Libraries!

Relapsed/Refractory Mantle Cell Lymphoma Care. Though mantle cell lymphoma (MCL) is incurable in most people, there have been major advancements in treatment options in recent years. Explore the resources ACCC has curated to assist community cancer programs with providing care for patients with relapsed/refractory MCL. Share this comprehensive collection of videos, articles, podcasts, and other tools with your colleagues today to help providers, patients, and caregivers navigate current treatment options.

Bispecific Antibodies. Prepare your cancer program for the successful integration of bispecific antibodies into community oncology practice with this new, comprehensive bank of materials. This resource library provides the multidisciplinary care team with training and resources, consensus recommendations, and information about policies and procedures. Explore evidence-based best practices for managing adverse events, evaluating and mitigating risks, and health literacy support today.